ifebemtinib (IN10018)

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim, InxMed

Drug class:

FAK inhibitor

Related drugs:

No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	IN10018 Sensitive: B - Late Trials IN10018 Sensitive : B	IN10018 Sensitive: B - Late Trials IN10018 Sensitive : B
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	MRTX1257 + IN10018 Sensitive: C3 – Early Trials MRTX1257 + IN10018 Sensitive : C3	MRTX1257 + IN10018 Sensitive: C3 – Early Trials MRTX1257 + IN10018 Sensitive : C3
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	sotorasib + IN10018 Sensitive: D – Preclinical sotorasib + IN10018 Sensitive : D	sotorasib + IN10018 Sensitive: D – Preclinical sotorasib + IN10018 Sensitive : D

Associations
(3)